SCHEMBL5135852

SCHEMBL5135852

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1cc(OC)ccc1OC)CC1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.40
HSP90AA1 P07900 2/20 0.37
HSP90AB1 P08238 2/20 0.37
ERBB2 P04626 1/20 0.37
BCHE P06276 5/20 0.36
TP53 P04637 2/20 0.35
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MEN1 O00255 2/20 0.35
LMNA P02545 2/20 0.35
KMT2A Q03164 2/20 0.35
ALDH1A1 P00352 1/20 0.35
CASP1 P29466 1/20 0.35
HTT P42858 1/20 0.35
CASP7 P55210 1/20 0.35
ADORA2B P29275 1/20 0.35
ADORA1 P30542 1/20 0.35
CRHR1 P34998 2/20 0.35
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135638 0.94 C5AR1 (0.39) C5AR1BCHEGAAMEN1LMNA
SCHEMBL5137556 0.92 C5AR1 (0.40) C5AR1BCHETP53ALDH1A1HDAC1
SCHEMBL5135791 0.89 C5AR1 (0.38) C5AR1BCHETP53GAASMN1; SMN2
SCHEMBL5137557 0.88 C5AR1 (0.42) C5AR1BCHETP53GAASMN1; SMN2
SCHEMBL648140 0.88 C5AR1 (0.44) C5AR1TP53GAASMN1; SMN2MEN1
SCHEMBL5137356 0.88 MEN1 (0.45) C5AR1HSP90AA1HSP90AB1SMN1; SMN2MEN1
SCHEMBL648304 0.88 C5AR1 (0.41) C5AR1BCHEMEN1KMT2AALDH1A1
SCHEMBL5135102 0.87 C5AR1 (0.42) C5AR1HSP90AA1HSP90AB1ERBB2BCHE
SCHEMBL5135642 0.86 C5AR1 (0.42) C5AR1HSP90AA1HSP90AB1ERBB2BCHE
SCHEMBL5135241 0.86 C5AR1 (0.42) C5AR1HSP90AA1HSP90AB1ERBB2BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed